Eli Lilly and Company is no stranger to the risky business of Alzheimer’s disease drug development, which may be why the big pharma is willing to place a high-risk bet on its newest amyloid-clearing therapy donanemab based on mixed results in the Phase II TRAILBLAZER-ALZ clinical trial. The company is converting its ongoing Phase IIb TRAILBLAZER-ALZ2 trial into a Phase III study, upping the number of patients and changing the endpoint to make its wager on donanemab a safer bet.
Lilly presented detailed results from TRAILBLAZER-ALZ during the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) and the data simultaneously...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?